Ying Yang

Dr. Ying Yang

The Children’s Hospital, Zhejiang University School of Medicine, National Clinical Research for Child Health
orcid

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 June 2020 in Journal of Medical Virology
Verified
Journal Article
Closed access
PDF file
YYYing Yang
Ying Yang
FGFeng Gao
Feng Gao

10 February 2022 in Diagnostics
Verified
Journal Article
Open access
PDF file
YYYing Yang
Ying Yang
HWHong-Jiao Wang
Hong-Jiao Wang
WHWeilin Hu
Weilin Hu
GBGUANNAN BAI
GUANNAN BAI
CHChun-Zhen Hua
Chun-Zhen Hua
Interferon-gamma release assays (IGRAs) are widely used in the diagnosis of Mycobacterium tuberculosis (M. tuberculosis) infection by detecting interferon-γ released by previously sensitized T-cells in-vitro. Currently, there are two assays based on either enzyme-linked immunosorbent assay (ELISA) or enzyme-linked immunospot (ELISPOT) technology, with several generations of products available. The diagnostic value of IGRAs in the immunocompromised population is significantly different from that in the immunocompetent population because their results are strongly affected by the host immune function. Both physiological and pathological factors can lead to an immunocompromised situation. We summarized the diagnostic value and clinical recommendations of IGRAs for different immunocompromised populations, including peoplewith physiological factors (pregnant and puerperal women, children, and older people), as well as people with pathological factors (solid organ transplantation recipients, combination with human immunodeficiency virus infection, diabetes mellitus, end-stage renal disease, end-stage liver disease, and chronic immune-mediated inflammatory diseases). Though the performance of IGRAs is not perfect and often requires a combination with other diagnostic strategies, it still has some value in the immunocompromised population. Hopefully, the newly developed IGRAs could better target this population.

23 September 2024 in Journal of Medical Virology
Verified
Journal Article
Closed access
HLHuamei Li
Huamei Li
YYYing Yang
Ying Yang
RTRan Tao
Ran Tao
SSShiqiang Shang
Shiqiang Shang

19 June 2023 in Vaccines
Verified
Journal Article
Open access
PDF file
YYYing Yang
Ying Yang
LHLisu Huang
Lisu Huang
Nowadays, people all over the world have been receiving different types of coronavirus disease 2019 (COVID-19) vaccines. While their effectiveness has been well recognized, various post-vaccination disorders are not fully understood. In this review, we discuss neurological disorders related to vascular, immune, infectious, and functional factors following COVID-19 vaccination, and attempt to provide neuroscientists, psychiatrists, and vaccination staff with a reference for the diagnosis and treatment of these diseases. These disorders may present as a recurrence of previous neurological disorders or new-onset diseases. Their incidence rate, host and vaccine characteristics, clinical manifestations, treatment, and prognosis differ significantly. The pathogenesis of many of them remains unclear, and further studies are needed to provide more evidence. The incidence rate of severe neurological disorders is relatively low, most of which are reversible or treatable. Therefore, the benefits of vaccination outweigh the risk of COVID-19 infection, especially among fragile populations.

21 January 2024 in Clinica Chimica Acta
Verified
Journal Article
Closed access
YYYing Yang
Ying Yang
YHYiting Hu
Yiting Hu
CYCheng Yang
Cheng Yang
WSWen Shi
Wen Shi
SJSufeng Jin
Sufeng Jin
KJKewen Jiang
Kewen Jiang